Likes Subject
Reminder: Amarantus Signs Non-Binding Term Sheet to Divest freegriff 07/23/22 9:05 AM
Gerald Commissiong you're the best M-F in town Lolo12 01/31/23 9:02 AM
AGREE !!! This clown needs to be choctaw 01/29/23 1:24 PM
EMA Financial, where this dilution is occasionally generating, freegriff 01/28/23 9:56 PM
there is no website for AMBS JPetroInc 01/28/23 11:43 AM
AMBS trending up. Would be good
Stuville 01/25/23 5:52 PM
not bad reasoning JPetroInc 01/16/23 8:44 AM
Don might be that CEO. I want to freegriff 01/14/23 5:30 AM
MANF needs to get out of mouse testing JPetroInc 01/13/23 9:54 AM
Biggest MANF Research yet! "Given the hierarchical order
freegriff 01/13/23 9:46 AM
Gerald Commissiong's CEO Blog says it all... JPetroInc 12/28/22 9:53 AM
close to all time bottom $0.0014 JPetroInc 12/06/22 4:01 PM
day trader jiggy for pocket change...! JPetroInc 11/21/22 12:53 PM
$AMBS @ .0035! Estrella 11/21/22 9:40 AM
Would be great if there was some good
Stuville 11/20/22 10:15 AM
I've not detected any changes in fundamentals. Still
freegriff 11/18/22 7:11 PM
Hey Freegriff. What's your read on the Stuville 11/18/22 4:19 PM
Boom lets go! i_like_bb_stock 11/18/22 3:16 PM
Anyone know what is behind the breakout? Stuville 11/18/22 2:34 PM
$AMBS BREAKOUT MODE CEO Best friend 11/18/22 1:33 PM
$AMBS what an opening Huge bids Huge loading CEO Best friend 11/18/22 9:50 AM
hopefully i_like_bb_stock 11/17/22 4:58 PM
Perhaps AMBS SP bump a leading indicator of Stuville 11/17/22 4:57 PM
moving here remember they own a big i_like_bb_stock 11/17/22 2:02 PM
you guessed this prediction right JPetroInc 11/15/22 1:40 PM
$AMBS Huge support 005 coming? CEO Best friend 11/15/22 12:58 PM
les you are prolly 1 of the more JPetroInc 11/07/22 9:48 AM
the stark and revealing reality of Gerald Commissiong JPetroInc 11/07/22 8:50 AM
Seems rats are getting all the benefits. leslunier 11/07/22 7:03 AM
Shareholders need: sharp63 11/06/22 8:52 AM
no need to point this out each time. freegriff 11/06/22 12:04 AM
More rat models....sigh JPetroInc 11/05/22 11:26 AM
More new MANF research freegriff 11/05/22 12:37 AM
whats to recover here...? JPetroInc 11/04/22 10:17 AM
happened oct 17th too, big block sells. apparently freegriff 11/04/22 8:50 AM
down today 38% on 5-Mil. share volume JPetroInc 11/02/22 6:52 PM
Up nicely today on over 4M shares volume. Stuville 11/01/22 4:15 PM
rats & mice been tested for years.... JPetroInc 10/30/22 7:50 PM
Waaaaaaaay more testing now than in 2008, each freegriff 10/29/22 10:57 AM
more mice testing - been going on since JPetroInc 10/29/22 9:58 AM
$AMBS Another MANF Gene Therapy Article from Cambridge/Sweden/Belgium: freegriff 10/29/22 4:13 AM
good one...lolzzz JPetroInc 10/28/22 9:46 PM
Bro has his family renting a modest 4bed freegriff 10/28/22 8:55 PM
"You mean never giving up" JPetroInc 10/25/22 10:00 PM
What he did to shareholders? You mean never freegriff 10/22/22 3:25 AM
what GC did to AMBS shareholders should be criminal JPetroInc 10/20/22 8:40 AM
Surprise, surperise, surprise. Not leslunier 10/18/22 6:47 AM
Note 9 – Subsequent Events On August 15, freegriff 10/17/22 5:38 PM
"will benefit if we're still standing...." JPetroInc 10/03/22 7:49 AM
Shareholders aren't paying for any of these studies freegriff 10/01/22 3:02 AM
yeah there's a lot of confusion as to JPetroInc 09/27/22 3:31 PM
Likes Subject

01/29/23 1:24 PM
01/28/23 11:43 AM
01/25/23 5:52 PM
01/16/23 8:44 AM
01/14/23 5:30 AM
01/13/23 9:54 AM
12/28/22 9:53 AM
12/06/22 4:01 PM
11/21/22 12:53 PM
11/21/22 9:40 AM
11/20/22 10:15 AM
11/18/22 4:19 PM
11/18/22 3:16 PM
11/18/22 2:34 PM
CEO Best friend
11/18/22 1:33 PM
CEO Best friend
11/18/22 9:50 AM
11/17/22 4:58 PM
11/17/22 2:02 PM
11/15/22 1:40 PM
CEO Best friend
11/15/22 12:58 PM
11/07/22 9:48 AM
11/07/22 7:03 AM
11/06/22 8:52 AM
11/06/22 12:04 AM
11/05/22 11:26 AM
11/05/22 12:37 AM
11/04/22 10:17 AM
11/02/22 6:52 PM
11/01/22 4:15 PM
10/30/22 7:50 PM
10/29/22 10:57 AM
10/29/22 9:58 AM
10/28/22 9:46 PM
10/28/22 8:55 PM
10/25/22 10:00 PM
10/22/22 3:25 AM
10/18/22 6:47 AM
10/17/22 5:38 PM
10/03/22 7:49 AM
09/27/22 3:31 PM

Amarantus Bioscience Holdings Inc. (AMBS)

Posts (Today)
Posts (Total)
Moderators JPetroInc freegriff
Amarantus BioScience Holdings develops and maintains interests in its biotechnology focused subsidiary companies briefly described below:

1. Elto Pharma, Inc. 50.1%-owned by Amarantus in partnership with Psychogenics. Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for the treatment of Parkinson's disease levodopa-induced dyskinesia, Alzheimer’s aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. Dr. Paula Trzepacz, formerly Senior Medical Fellow in Neurosciences drug development at Eli Lilly, serves as Elto Pharma’s Chief Medical Advisor. The combined therapeutic market for Parkinson’s Alzheimer’s and ADHD treated by eltoprazine is estimated to be over $30B.

2. Cutanogen Corporation: 90.1% owned by Amarantus. Cutanogen Corporation is preparing for pivotal studies with Engineered Skin Substitute (ESS) for the treatment of pediatric life-threatening severe burns. ESS is a regenerative medicine-based, autologous full-thickness skin graft technology originally developed by the Shriner’s Hospital that can be used to treat severe burns, as well as several other catastrophic and cosmetic dermatological indications. Dr. Richard Kagan, formerly Chief of Staff at the Shriners Burn Hospital in Cincinnati and past President of the American Burn Association, serves as Chief Medical Advisor for Cutanogen Corporation. The market for skin-grafting related disorders is estimated at $5B.

3. MANF Therapeutics, Inc.: 100% owned by Amarantus. MANF Therapeutics Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (“MANF”). MANF Therapeutics is developing MANF-based products as treatments for ophthalmological disorders such as Wolfram’s Syndrome, Retinitis Pigmentosa and Glaucoma, as well as neurodegenerative diseases such as Parkinson’s disease. MANF was discovered by the Company’s Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS’ proprietary discovery engine PhenoGuard, and believes several other neurotrophic factors remain to be discovered. Dr. John Commissiong, formerly Head of the Neurotrophic Factors Group at the National Institute of Neurological Disease and Stroke, serves as Chief Scientific Advisor to MANF Therapeutics. The combined market for indications treated by MANF exceeds $50B.

4. Security interests in Todos Medical ($TOMDF) and Theralink Technologies ($OBMP) (f/k/a Avant Diagnostics, Inc.), owning 78 million shares of Todos Medical, and 31.5% of Theralink prior to completion of corporate restructuring of Theralink Technologies, which is in progress. The restructuring will likely result in a dilution of the Company’s ownership.

5. Security Interests in Hempori, Inc. Amarantus has a 51% interest in Hempori, a revenue-generating distributor of CBD and other Cannabis related products in Texas.
              Share Structure and Security Details (as of 3/19/2022)                       Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF)                                  Experienced Management                                    

MANF was discovered by Chief Scientific Officer John Commissiong is emerging as one of the greatest scientific discoveries in modern biotechnology with preclinical research indicating therapeutic potential in dozens of indications, with more potential applications being discovered through growing research interest each year. A brief review of the scientific literature is available at the following link:
Potential Indications served by AMBS Assets
 Parkinson's Disease (PD)
 Amyotrophic Lateral Sclerosis (ALS) - Lou Gehrig's Disease 
 Ischemic Heart Disease
 Alzheimer's Disease (AD)
 Huntington's Disease
 Traumatic Brain Injury/ Chronic Traumatic Encephalopathy (TBI/CTE)
ischaemic stroke
Bipolar Disorder
Acute Lung Injury (ALI)
Post-ischemic neurological recovery
non-alcoholic steatohepatitis (NASH)
maintaining circadian plasticity of neurons
Umbilical Cord Mesenchymal Stem Cells for treating Spinal Cord Injury 
Charcot-Marie-Tooth disease (CMT)
cancer immunotherapy
Retinitis Pigmentosa (RP); and,
other Inherited Retinal Disorders
Multiple Sclerosis Experimental autoimmune encephalomyelitis
Control of Energy Homeostasis
Liver Damage
Heart Attack 
Bacterial Myocarditis
Age-related macular degeneration
MANF in Acetaminophen (APAP)-induced liver injury (AILI) 
Post-Operative Delirium via Inhibiting Inflammation and Microglia Activation
Sporadic Retinal Disorders
Other degenerative disorders and retinal injury
Wolfram's Syndrome
Diabetes Type-1
Diabetes Type-2
type 2 diabetes mellitus
alcoholic pancreatitis
Septic Renal Injury
Colorectal Cancer
Diagnosis of Parkinson's Disease
Assays for diagnosis and therapeutics
47 Protein Biomarkers for Neurodegenerative Diseases
Assays for Amyotrophic Lateral Sclerosis (ALS) and ALS-like disorders
Diagnosis of Alzheimer's Disease
Alzheimer's Disease (AD)
Parkinson's Disease Levodopa Induced Dyskinesia (PD-LID)
Attention Deficit Hyperactivity Disorder (ADHD)
Lipidomics Assay
Exosomes Assay
Four additional Assays
Congenital Hairy Nevus
Type 3 and 4 intractable severe burns
MSPrecise Diagnostic for Multiple Sclerosis (MS)
Neurosarcoid Diagnostic Assay
Neuromeylitis optica Diagnostic Assay
Para neoplastic Disease Diagnostic Assay
Amyotrophic Lateral Sclerosis (ALS) Diognostic Assay
Atopic Dermatitis
Skeletal Muscle Regeneration

Most Liked Posts
(Last 30 Days)
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
AMBS Latest News
New Post